Ipamorelin
Also known as · NNC 26-0161 · Selective GH secretagogue · Aib-His-D-2-Nal-D-Phe-Lys-NH2
- EvidencePreclinical
- CategoryGH secretagogue
- RoutesubQ
- Half-life~2 hours
- Form
- Lyophilized powder
- Purity
- ≥98% (HPLC)
- Molecular formula
- C38H49N9O5
- Molecular weight
- 711.9 g/mol
- CAS number
- 170851-70-4
- Sequence
- Aib-H-(D-2Nal)-(D-Phe)-K-NH2
- COA
- Available on request
In stock
Request pricing
Contact us for current pricing and bulk quotes.
Reserve vial →For research use only. Not for human consumption. Buyers must be affiliated with a research institution.
01 / Research summary
What the literature reports
Ipamorelin is a synthetic pentapeptide built on non-proteinogenic residues (Aib, D-2-naphthyl-alanine, D-phenylalanine). It acts as a selective agonist of the ghrelin / growth-hormone-secretagogue receptor (GHS-R1a).
Cellaire classifies Ipamorelin as preclinical evidence. Its defining publication by Raun et al. (Eur J Endocrinol 1998) characterized it as the first GH-selective secretagogue — releasing growth hormone in rat pituitary cells and conscious swine while leaving FSH, LH, prolactin, TSH, ACTH, and cortisol essentially unaffected. Ipamorelin remains actively listed as FDA 503B Category 2 as of 2023.
02 / Reconstitution
Reconstitution reference
Illustrative unit math for a 10 mg vial reconstituted with 2 mL bacteriostatic water. This is not a dose recommendation.
03 / Overview
Molecular overview
Ipamorelin is the pentapeptide Aib-His-D-2Nal-D-Phe-Lys-NH2, where Aib is α-aminoisobutyric acid and 2Nal is 2-naphthyl-alanine. Both non-proteinogenic residues confer protease resistance.
The peptide binds GHS-R1a (the ghrelin receptor) with a selectivity profile that leaves cortisol, prolactin, and gonadotropins unchanged in preclinical models — a contrast with earlier GH secretagogues like GHRP-6.
No approved indication exists in the United States or Europe. Ipamorelin appears on the FDA 503B Category 2 bulk substance list published in 2023.
Human data are limited to a small unpublished phase-2 program in post-operative ileus that was discontinued.
04 / References